The British drugmaker AstraZeneca expects to roll out a successful vaccine in late December or early 2021
The Serum Institute of India, world's largest vaccine maker, is boosting the production of AstraZeneca's Covid-19 shot aiming to get 100 million doses ready by December.
The institute will get authorisation from the Indian government if the final-stage trial data of AstraZeneca's vaccine candidate gives effective protection from the virus, said Chief Executive Officer of the institute Adar Poonawalla, reports Bloomberg.
An inoculation drive is likely to begin across India in December if the institute gets the authorisation.
The Serum Institute of India has partnered with AstraZeneca to produce at least one billion doses of the vaccine.
They have already manufactured 40 million doses of the vaccine, under the at-risk manufacturing and stockpiling licence from Drugs Controller General of India.
The vaccine made in the UK is currently being tested in large efficacy trials in the UK, Brazil, South Africa, and the US.
Bangladesh is also set to get the same vaccine as a memorandum of understanding (MOU) was signed between the Serum Institute of India and Beximco Pharmaceuticals.
The British drugmaker AstraZeneca expects data from late-stage trials of the vaccine later this year.
The company has taken on the development of Oxford University's potential Covid-19 vaccine and signed several deals to supply over three billion doses to countries around the world.
Expectations are that Britain could start rolling out a successful vaccine in late December or early 2021.
The Serum Institute of India also plans to start manufacturing Novavax Inc’s vaccine contender soon.